 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ABBV-1088 / AbbVie
Journal: UQCRC1 deficiency impairs mitophagy via PINK1-dependent mechanisms in Parkinson's disease. (Pubmed Central) - Jan 16, 2026
Treatment with two PINK1 activators, kinetin and MTK458, resulted in similar protective effects in the fly and cell models. Overall, we identified OXPHOS stress led by deficiency of UQCRC1 as an etiology of mitophagy defects in PD and PINK1 as a therapeutic target for UQCRC1-associated PD.
- | ABBV-1088 / AbbVie
Journal: Astragaloside IV alleviates D-GAL-induced endothelial cell senescence by promoting mitochondrial autophagy via inhibiting the PINK1/Parkin pathway (Pubmed Central) - Nov 28, 2025
Overall, we identified OXPHOS stress led by deficiency of UQCRC1 as an etiology of mitophagy defects in PD and PINK1 as a therapeutic target for UQCRC1-associated PD. AS-IV alleviates D-GAL-induced endothelial cell senescence by inhibiting the PINK1/Parkin pathway to regulate mitochondrial autophagy.
- | ABBV-1088 / AbbVie
Journal: Putative PINK1/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress. (Pubmed Central) - Aug 31, 2025
Here, we characterize two mitophagy activators: a novel Parkin activator, FB231, and the reported PINK1 activator MTK458...Our findings support a model whereby weak or "silent" mitochondrial toxins potentiate other mitochondrial stressors, enhancing PINK1/Parkin-mediated mitophagy. These insights highlight important considerations for therapeutic strategies targeting mitophagy activation in Parkinson's disease.
- || ABBV-1088 / AbbVie
Enrollment closed: A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088 (clinicaltrials.gov) - Aug 15, 2025
P1, N=72, Active, not recruiting, Sponsor: AbbVie
These insights highlight important considerations for therapeutic strategies targeting mitophagy activation in Parkinson's disease. Recruiting --> Active, not recruiting
- | ABBV-1088 / AbbVie
Preclinical, Journal: PINK1 activation by MTK458 ameliorates neurological impairments and pyroptosis after intracerebral hemorrhage in mice. (Pubmed Central) - Jun 5, 2025
and IL-18. These results suggest that MTK458 effectively reduces neurological impairments, brain edema, and anxiety-related behaviors in mice following ICH, highlighting PINK1 activation as a promising therapeutic strategy for ICH-induced neurological deficits.
- ||| ABBV-1088 / AbbVie
Trial completion: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. (clinicaltrials.gov) - Feb 19, 2025
P1, N=60, Completed, Sponsor: AbbVie
These results suggest that MTK458 effectively reduces neurological impairments, brain edema, and anxiety-related behaviors in mice following ICH, highlighting PINK1 activation as a promising therapeutic strategy for ICH-induced neurological deficits. Active, not recruiting --> Completed
- || ABBV-1088 / AbbVie
Enrollment closed: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. (clinicaltrials.gov) - Jan 24, 2025
P1, N=60, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| ABBV-1088 / AbbVie
Enrollment open: A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088 (clinicaltrials.gov) - Sep 20, 2024
P1, N=66, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| ABBV-1088 / AbbVie
New P1 trial: A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088 (clinicaltrials.gov) - Aug 30, 2024
P1, N=66, Not yet recruiting, Sponsor: AbbVie
- || ABBV-1088 / AbbVie
Enrollment open: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. (clinicaltrials.gov) - May 21, 2024
P1, N=48, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || ABBV-1088 / AbbVie
New P1 trial: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. (clinicaltrials.gov) - May 15, 2024
P1, N=48, Not yet recruiting, Sponsor: AbbVie
- MTK-458 / Mitokinin
SMALL MOLECULE PINK1 ACTIVATORS RESCUE MITOCHONDRIA-ASSOCIATED PATHOLOGY IN IDIOPATHIC PARKINSON'S DISEASE MODELS (On-Demand Oral Gallery D) - Dec 23, 2022 - Abstract #ADPD2023ADPD_785;
Not yet recruiting --> Recruiting Our data support the clini cal development of PINK1 activators as disease -modifying therapeutics for the treatment of idiopathic PD.